2026-09-29T11:40:27.000Z · 4 days ago Medicus Pharma submits optimized Teverelix registrational protocol to FDA
Sep 29, 2026, 7:30 AM EDT · 4 days ago Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
2026-09-21T11:40:33.000Z · 12 days ago Medicus to focus future clinical development of SkinJect on Gorlin syndrome
Sep 21, 2026, 7:30 AM EDT · 12 days ago Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
2026-09-14T11:05:43.000Z · 19 days ago Medicus Pharma price target raised to $1 from 90c at Alliance Global
Sep 10, 2026, 7:30 AM EDT · 23 days ago Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Sep 8, 2026, 7:30 AM EDT · 25 days ago Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
2026-08-17T12:55:34.000Z · 6 weeks ago Medicus Pharma price target lowered to 90c from $1 at Alliance Global
Aug 12, 2026, 6:00 PM EDT · 7 weeks ago Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 3, 2026, 7:30 AM EDT · 2 months ago Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
2026-07-31T11:37:05.000Z · 2 months ago Medicus Pharma Teverelix granted investigational new drug authorization in UAE
Jul 31, 2026, 7:30 AM EDT · 2 months ago Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
2026-07-27T13:10:48.000Z · 2 months ago Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study
Jul 27, 2026, 8:17 AM EDT · 2 months ago Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
2026-07-16T11:40:11.000Z · 2 months ago Medicus Pharma receives FDA feedback, IRB approval for Teverelix study
Jul 16, 2026, 7:30 AM EDT · 2 months ago Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Jun 22, 2026, 7:30 AM EDT · 3 months ago Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
2026-06-15T11:51:23.000Z · 3 months ago Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
Jun 15, 2026, 7:30 AM EDT · 3 months ago Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Jun 11, 2026, 7:30 AM EDT · 3 months ago Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program UAE
2026-06-08T11:37:41.000Z · 3 months ago Medicus Pharma submits substantial modification application through EU CTIS
Jun 8, 2026, 7:30 AM EDT · 3 months ago Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Jun 3, 2026, 8:00 AM EDT · 4 months ago Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
May 14, 2026, 4:30 PM EDT · 4 months ago Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07T03:48:38.000Z · 4 months ago Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis
May 6, 2026, 7:30 AM EDT · 5 months ago Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
2026-04-27T13:31:02.000Z · 5 months ago Medicus Pharma meets with lawmakers to support SkinJect designations
Apr 27, 2026, 7:30 AM EDT · 5 months ago Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
2026-04-17T11:35:50.000Z · 5 months ago Medicus Pharma submits ODD application to U.S. FDA for SkinJect
Apr 17, 2026, 7:30 AM EDT · 5 months ago Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Apr 15, 2026, 7:30 AM EDT · 5 months ago Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
2026-04-07T14:23:02.000Z · 5 months ago Medicus Pharma enters media partnership with New to The Street
2026-04-06T11:37:11.000Z · 6 months ago Medicus Pharma submits clinical study design to FDA for Teverelix
Apr 6, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Apr 1, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
2026-03-30T13:38:08.000Z · 6 months ago Medicus Pharma reports principal investigator validation of Phase 2 data
Mar 30, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Mar 26, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
Mar 25, 2026, 4:30 PM EDT · 6 months ago Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Mar 18, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Mar 16, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
Mar 10, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Mar 9, 2026, 7:30 AM EDT · 6 months ago Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
Mar 5, 2026, 7:30 AM EST · 7 months ago Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
Mar 3, 2026, 7:30 AM EST · 7 months ago Medicus Pharma To Participate in the 38th Annual Roth Conference
Feb 10, 2026, 7:30 AM EST · 7 months ago Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
Jan 23, 2026, 7:30 AM EST · 8 months ago Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
Jan 22, 2026, 7:30 AM EST · 8 months ago Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Jan 20, 2026, 7:30 AM EST · 8 months ago Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
Jan 12, 2026, 7:30 AM EST · 8 months ago Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
Jan 5, 2026, 7:30 AM EST · 9 months ago Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
Dec 22, 2025, 7:30 AM EST · 9 months ago Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Dec 15, 2025, 7:30 AM EST · 9 months ago Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Dec 5, 2025, 3:20 PM EST · 10 months ago Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Dec 1, 2025, 8:00 AM EST · 10 months ago Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Nov 24, 2025, 8:00 AM EST · 10 months ago Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
Nov 17, 2025, 7:30 AM EST · 10 months ago Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Nov 14, 2025, 5:00 PM EST · 10 months ago Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Nov 13, 2025, 7:30 AM EST · 10 months ago Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Oct 29, 2025, 7:30 AM EDT · 11 months ago Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Oct 29, 2025, 7:30 AM EDT · 11 months ago Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Oct 22, 2025, 7:30 AM EDT · 11 months ago Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Oct 14, 2025, 8:07 AM EDT · 11 months ago The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
